...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Npj - Primary Care Respiratory Medicine >Beta-agonist overuse and delay in obtaining medical review in high risk asthma: a secondary analysis of data from a randomised controlled trial
【24h】

Beta-agonist overuse and delay in obtaining medical review in high risk asthma: a secondary analysis of data from a randomised controlled trial

机译：β-激动剂过度使用和高危哮喘患者获得医学检查的延迟：来自随机对照试验的数据的二次分析

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Asthma mortality surveys report delays in seeking medical review and overuse of beta-agonist therapy as factors contributing to a fatal outcome. However, the strength of these associations is limited because many asthma deaths are unwitnessed. We undertook a secondary analysis of data from a 24-week randomised controlled trial of 303 patients with high-risk asthma, randomised to combination budesonide/formoterol inhaler according to a single maintenance and reliever therapy regimen or fixed dose budesonide/formoterol with salbutamol as reliever (Standard) regimen. Medication use was measured by electronic monitors. The thresholds for high, marked and extreme beta-agonist use days were defined in the single maintenance and reliever therapy arm as: >8, >12 and >16 actuations of budesonide/formoterol in excess of four maintenance doses, respectively; and in the Standard arm as: >16, >24 and >32 actuations of salbutamol, respectively. Whether a medical review was obtained within 48鈥塰 of an overuse episode was determined by review of data collected during the study by participant report. The mean (standard deviation) proportion of days in which high, marked and extreme beta-agonist overuse occurred without medical review within 48鈥塰 was 0路94(0路20), 0路94(0路15) and 0路94(0路17), and 0路92(0路19), 0路90(0路26) and 0路94(0路15) for single maintenance and reliever therapy and Standard regimens, respectively. In at least 90% of days, in which beta-agonist overuse occurred, patients did not obtain medical review within 48鈥塰 of beta-agonist overuse, regardless of the magnitude of overuse or the inhaled corticosteroid/long-acting beta-agonist regimen.
机译：哮喘死亡率调查报告称，寻求医学复诊的延迟和过度使用β-激动剂是导致致命结果的因素。但是，由于许多哮喘死亡是目击者，因此这些关联的强度受到限制。我们对303名高危哮喘患者进行了为期24周的随机对照试验，对该数据进行了二次分析，并根据单一维持和缓解治疗方案或以沙丁胺醇为缓解剂量的固定剂量布地奈德/福莫特罗随机分配至布地奈德/福莫特罗联合吸入剂（标准）疗程。药物的使用由电子监控器测量。在单个维持和缓解治疗组中，高，显着和极端的β-激动剂使用天数的阈值定义为：布地奈德/福莫特罗的致动分别> 8，> 12和> 16，超过四个维持剂量;在标准臂中分别为：> 16，> 24和> 32沙丁胺醇致动。通过对参与者报告研究期间收集的数据进行审查，确定是否在过度使用发作后48分钟内获得了医学审查。在48分钟内未经医学检查就发生高，明显和极端β-激动剂过度使用的天的平均（标准差）比例为0路94（0路20），0路94（0路15）和0路94 （0路17）和0路92（0路19），0路90（0路26）和0路94（0路15）分别用于单一维护和缓解疗法以及标准方案。在至少90％的日子里，发生过β受体激动剂过度使用的情况，无论过度使用的程度如何，或吸入皮质类固醇/长效β受体激动剂的治疗方案，患者都不会在48英寸的β激动剂过度使用内获得医学检查。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号